home / stock / msclf / msclf news


MSCLF News and Press, Satellos Bioscience Inc. From 11/12/25

Stock Information

Company Name: Satellos Bioscience Inc.
Stock Symbol: MSCLF
Market: OTC
Website: satellos.com

Menu

MSCLF MSCLF Quote MSCLF Short MSCLF News MSCLF Articles MSCLF Message Board
Get MSCLF Alerts

News, Short Squeeze, Breakout and More Instantly...

MSCLF - Expected US Company Earnings on Wednesday, November 12th, 2025

RWE AG ADR (RWEOY) is expected to report $0.16 for Q3 2025 Hillenbrand Inc (HI) is expected to report $0.62 for Q4 2025 Ardent Health Inc. (ARDT) is expected to report $0.42 for Q3 2025 Quince Therapeutics Inc. (QNCX) is expected to report $-0.2 for Q3 2025 GlobalFoundries Inc. (G...

MSCLF - Satellos to Participate in November Investor Conferences

Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that its leadership team will present and participate in ...

MSCLF - Satellos Announces First Adult Patient Dosed in LT-001, an Open-Label, Long-Term Follow-Up Study of SAT-3247 in Duchenne Muscular Dystrophy

First returning adult patient from Phase 1b study recently dosed; additional returning patients being scheduled 11-month open-label study will evaluate functional outcomes, safety, muscle composition by MRI, and serum biomarkers Results following initial 3 months of treatm...

MSCLF - Satellos Announces New Data Further Demonstrating Safety, Tolerability, and Functional Impact of SAT-3247 in First-in-Human Trial of Adults with Duchenne Muscular Dystrophy

Adults with Duchenne muscular dystrophy demonstrated functional improvements exceeding natural history, following 28-day treatment with SAT-3247 Grip strength increased 118.6% and predicted forced vital capacity increased 5.8%; whereas, both decline in natural history SAT-...

MSCLF - Catalyst Watch: Eyes on the OpenAI event, Powell talk, PepsiCo earnings, and more IPOs

2025-10-03 15:44:51 ET More on the markets Should Investors Be Worried About Inflation? The ADP Report Says Layoffs Are Starting, Recession Is Near Macro Insights From September 2025: A Government Shutdown, The Fed's Gamble, And A Bubble Ready To Burst Kalshi...

MSCLF - Satellos to Present SAT-3247 Phase 1 Clinical Data in Late-Breaking Poster Session at the 2025 World Muscle Society Congress

Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that it will present two scientific posters at the 30th A...

MSCLF - Satellos Announces IND Submission to the U.S. FDA and Global Regulatory Filings to Advance a Phase 2 Clinical Trial of SAT-3247 in Children with Duchenne Muscular Dystrophy

Regulatory submissions filed in the U.S., UK, Europe, Serbia and Australia Three-month randomized placebo-controlled study to assess safety, pharmacokinetics, dose, muscle biopsies, and measures of function in ambulatory children First patient expected to b...

MSCLF - Satellos Bioscience: Promising Novel Treatment For Duchenne Muscular Dystrophy

2025-09-02 09:37:25 ET Toronto-based Satellos Bioscience (MSCL.TSX, MSCLF.OTCQB) is a clinical-stage small molecule development company focused on restoring natural muscle repair and regeneration for degenerative muscle diseases. Its proprietary discovery platform, MyoReGenX, identi...

MSCLF - Satellos Bioscience Inc. GAAP EPS of -$0.03

2025-08-13 09:46:55 ET More on Satellos Bioscience Inc. Historical earnings data for Satellos Bioscience Inc. Financial information for Satellos Bioscience Inc. Read the full article on Seeking Alpha For further details see: Satellos Bioscience Inc. GAAP ...

MSCLF - Satellos Reports Second Quarter 2025 Results and Highlights Upcoming Clinical Milestones

Reported positive Phase 1b data in five adults with Duchenne muscular dystrophy (DMD) after 28 days of treatment Demonstrated safety, tolerability and an approximate doubling in grip strength On track to initiate a follow-up of the Phase 1b study in adults with DMD in ...

Previous 10 Next 10